New combo aims to outsmart resistant breast cancer
NCT ID NCT04762979
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the targeted drug alpelisib to ongoing hormone therapy can help people with a specific genetic mutation (PIK3CA) in advanced breast cancer that has stopped responding to hormone therapy alone. About 44 participants will take daily alpelisib pills along with standard hormone-blocking injections or pills. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alpelisib (a targeted drug) combined with either fulvestrant or an aromatase inhibitor (hormone-blocking drugs)
What this could lead to
If successful, this could offer a new treatment option for people with a specific genetic mutation in advanced breast cancer that has stopped responding to hormone therapy alone.
What could go wrong
This is a small, early-phase trial (44 people) with no comparison group, so results may not apply broadly. Side effects from alpelisib can include high blood sugar, rash, and diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States